Honolulu, HINCT07095465Now EnrollingIRB Ready

Lewy Body Dementia Psychosis Clinical Trial in Honolulu, HI

Access cutting-edge lewy body dementia psychosis treatment through this phase 3 clinical trial at a research site in Honolulu. Study-provided care at no cost to qualified participants.

Sponsored by ACADIA Pharmaceuticals Inc.

Quick Self-Assessment

See if you qualify for this Honolulu location

Preparing your pre-screening questions…

Expert Care in Honolulu

Access lewy body dementia psychosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related lewy body dementia psychosis treatment provided free

Apply for This Honolulu Location

Check if you qualify for this lewy body dementia psychosis clinical trial in Honolulu, HI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Honolulu

    Convenient for HI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Honolulu site if eligible
  4. 4Begin participation

About This Lewy Body Dementia Psychosis Study in Honolulu

A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

Sponsor: ACADIA Pharmaceuticals Inc.

Who Can Participate

Inclusion Criteria

The subject may benefit from long-term therapy with open-label ACP-204 treatment in the judgment of the Investigator
Subject has completed Visit 6 (EOT) of the antecedent ACP-204-012 study and did not have an early discontinuation from the antecedent study
Can complete all study visits with a study partner/caregiver
Can understand the nature of the study and protocol requirements and provide written informed consent. If the subject is deemed not competent to provide informed consent, the following requirements for consent must be met:
The subject's LAR (or study partner/caregiver, if local regulations allow) must provide written informed consent.
The subject must provide written (if capable) informed assent per local regulations
If the subject is a female, she must be of nonchildbearing potential
If the subject is male, he must agree to the following during the study intervention period and for at least 90 days after the last dose of study drug:
Refrain from donating sperm, AND
Be abstinent from sexual intercourse where pregnancy can occur (abstinent on a long-term and persistent basis) and agree to remain abstinent OR
Use a condom and subject's female partner (if of childbearing potential and not pregnant) must use an additional contraceptive method

Exclusion Criteria

Is judged by the Investigator or the Medical Monitor to be inappropriate for the study for any reason
Is in hospice, is receiving end-of-life palliative care, or is bedridden
Has a heart rate \<50 beats per minute, as measured by vital signs at Baseline (EOT visit of the antecedent study). If bradycardia is secondary to iatrogenic or treatable causes and these causes are addressed, a heart rate assessment can be repeated.
Has a BMI \<18.5 kg/m2 or known unintentional weight loss ≥7% of body weight over past 6 months
Has a clinically significant laboratory abnormality in the antecedent ACP-204-012 study, excepting at ACP-204-012 EOT, that in the judgment of the Investigator or Medical Monitor, will either:
jeopardize the safe participation of the subject in this study; OR
interfere with the conduct or interpretation of safety or efficacy evaluations in the study
Is actively suicidal at Visit 1 (Baseline, EOT visit of the antecedent study)
Has a neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical or mental disorder, including cancer or malignancies that, in the judgment of the Investigator, would increase the risk associated with taking study medication or significantly interfere with the conduct or interpretation of the study
Requires treatment with a medication or other substance that is prohibited by the protocol or will be used in a way that violates a use restriction

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Honolulu?

Yes, this clinical trial (NCT07095465) has an active research site in Honolulu, HI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Lewy Body Dementia Psychosis Treatment Options in Honolulu, HI

If you're searching for lewy body dementia psychosis treatment options in Honolulu, HI, this clinical trial (NCT07095465) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Honolulu research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced lewy body dementia psychosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all lewy body dementia psychosis clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Honolulu, HI

See all alzheimers disease clinical trials recruiting in Honolulu — not just this study.

Browse Alzheimers Disease Trials in Honolulu →

Browse More Trials by Condition

Alzheimers Disease TrialsSchizophrenia TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Honolulu?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Honolulu, HI